These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6415441)

  • 1. [Therapeutic defibrinogenation as conservative therapy of peripheral arterial occlusive disease. A critical analysis].
    Ernst E
    MMW Munch Med Wochenschr; 1983 Sep; 125(37):796-8. PubMed ID: 6415441
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic lowering of fibrinogen levels].
    Ernst E
    MMW Munch Med Wochenschr; 1983 May; 125(21):83-4. PubMed ID: 6410202
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic defibrinogenation in peripheral vascular disease.
    Ernst E
    Int Angiol; 1985; 4(3):373-7. PubMed ID: 3913715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodilution combined with defibrinogenation.
    Böhme H; Everts B
    Bibl Haematol; 1981; (47):165-72. PubMed ID: 7039611
    [No Abstract]   [Full Text] [Related]  

  • 5. [Studies on blood coagulation systems during defibrinogenation therapy with batroxobin (Bothrops atrox venom) (author's transl)].
    Ishimaru S; Konishi M; Furukawa K; Takahashi M; Fujimaki M
    Rinsho Ketsueki; 1979 May; 20(5):500-9. PubMed ID: 465131
    [No Abstract]   [Full Text] [Related]  

  • 6. Defibrinating agents: effects on blood rheology, blood flow and vascular diseases in controlled studies.
    Lowe GD
    Bibl Haematol; 1981; (47):247-51. PubMed ID: 7039612
    [No Abstract]   [Full Text] [Related]  

  • 7. Proceedings: Clinical improvement in peripheral circulation by controlled defibrinogenation.
    Dormandy JA; Goyle KB
    Br J Surg; 1976 Aug; 63(8):661-2. PubMed ID: 953495
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of treatment with ancrod (Arwin) in 21 patients with chronic arterial occlusive disease].
    Rosendo A; Sala Planell E; Latorre J; Marinello J; Olba L; Rutllant ML
    Rev Clin Esp; 1982 Mar; 164(5):313-6. PubMed ID: 7100546
    [No Abstract]   [Full Text] [Related]  

  • 9. [Defibrination-therapy using a thrombin-like snake venom enzyme (Defibrase) Blood-coagulation physiological studies and clinical experiences].
    Martin M; Engelken HJ; Tambert F; Martin U; Hirdes E; Auel H
    Vasa Suppl; 1976; 5():1-39. PubMed ID: 1070197
    [No Abstract]   [Full Text] [Related]  

  • 10. [Improvement of flow properties of blood: a new principle for drug therapy of chronic peripheral arterial vascular disorders].
    Ehrly AM
    Vasa Suppl; 1973; 1():1-18. PubMed ID: 4517911
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medical treatment of peripheral occlusive arteriopathies. Possibilities, principles and basis].
    Heidrich H
    Minerva Med; 1979 Oct; 70(47):3255-63. PubMed ID: 390422
    [No Abstract]   [Full Text] [Related]  

  • 12. Internation Committee on Thrombosis and Haemostasis Basil, 8.-11. September 1974 Subcommittee on Clinical Investigations: Registry of prospective clinical trials.
    Verstraete M
    Thromb Diath Haemorrh; 1975 Jun; 33(3):655-63. PubMed ID: 125464
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term results after defibrinogenation by Arwin in chronic occlusive arterial disease.
    Staiger J; Konrad-Graf S; Keil G
    Bibl Haematol; 1981; (47):252-7. PubMed ID: 7337665
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fibrinolytic and defibrinogenation therapy].
    Mannucci PM; Mari D
    Ric Clin Lab; 1983; 13 Suppl 3():245-55. PubMed ID: 6672998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Defibrinating treatment in children with severe nephrotic syndrome].
    Grygalewicz J; Ostojska J
    Pediatr Pol; 1978 Apr; 53(4):531-6. PubMed ID: 652447
    [No Abstract]   [Full Text] [Related]  

  • 16. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination hemodilution and defibrinogenating therapy in chronic arterial occlusive diseases].
    Ehrly AM; Saeger-Lorenz K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():332-3. PubMed ID: 349931
    [No Abstract]   [Full Text] [Related]  

  • 18. Controlled evaluation of drugs in chronic vascular disease.
    Trübestein G
    Angiology; 1981 Oct; 32(10):699-704. PubMed ID: 6173001
    [No Abstract]   [Full Text] [Related]  

  • 19. Derivatives of fibrinogen and fibrin during defibrase therapy. Separation of high and low molecular weight derivatives of fibrinogen and fibrin by agarose gel filtration.
    Asbeck F; Lechler E; Martin M; van de Loo J
    Haemostasis; 1974; 3(5-6):340-7. PubMed ID: 4468232
    [No Abstract]   [Full Text] [Related]  

  • 20. [Arterial occlusive disease: reducing blood viscosity through drugs].
    Gnauen H
    Med Klin; 1981 Feb; 76(5):144-6. PubMed ID: 7219342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.